Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Oncology/Hematology Market Research

Immune Checkpoint Inhibitors Market by Type (PD-1 Inhibitors, PD-L1 Inhibitors and CTLA-4 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma and other application): Global Opportunity Analysis and Industry Forecast, 2021-2

Best Price Guarantee Length Publisher Published Date SKU
from $4,125 160 Pages Allied Market Research January, 2022 ALMR17046153
Best Price Guarantee
Price from $4,125
Length 160 Pages
Publisher Allied Market Research
Published Date January, 2022
SKU ALMR17046153

Immune Checkpoint Inhibitors Market by Type (PD-1 Inhibitors, PD-L1 Inhibitors and CTLA-4 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma and other application): Global Opportunity Analysis and Industry Forecast, 2021-2030

The global immune checkpoint inhibitors market was valued at $29,803.71 million in 2020, and is projected to reach $1,40,890.10 million by 2030, registering a CAGR of 16.8% from 2021 to 2030

Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells, as these affect the functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins including, CTLA-4 (cytotoxic T lymphocyte associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death ligand 1).

Immune checkpoint inhibitor is also known as checkpoint inhibitor therapy is a form of cancer immunotherapy. Which used in the treatment of a broad spectrum of cancers as metastatic melanoma, non-small lung cancer or renal cell carcinoma. These are humanized monoclonal antibodies target inhibitory receptors (e.g. CTLA-4, PD-1, LAG-3, TIM-3) and ligands (PD-L1) expressed on T lymphocytes, antigen presenting cells and tumor cells and elicit an anti-tumor response by stimulating immune system.

The key factor that drives the growth of market are owing to the growth in incidence of different forms of cancer, surge in awareness of checkpoint inhibitor for treatment of cancer, higher number of R&D studies, and surge in adoption of immune checkpoint inhibitor drugs. In addition, growth in the geriatric population, and technological advancement in screening & diagnosis of cancer further drives the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth.

The global immune checkpoint inhibitor market is segmented based on type, application, and region. Based on type, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. According to the application, the market is categorized as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others.

Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, and rest of LAMEA).

Key players operating in the global immune checkpoint inhibitor market are, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.) GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), and BeiGene Ltd Shanghai Jhunsi Biosciences Ltd.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global immune checkpoint inhibitors market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps to understand the products and end users of immune checkpoint inhibitors used across the globe.
Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS


By Type

CTLA-4 Inhibitor
PD-1 Inhibitor
PD-L1 Inhibitor

By Application

Lung Cancer
Bladder Cancer
Melanoma
Hodgkin lymphoma
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Rest of LAMEA

KEY Players

AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company (ARMO Biosciences.)
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
Sanofi
Merck & Co., Inc.
Merck KGaA (EMD Serono, Inc.)
BeiGene Ltd
Shanghai Jhunsi Biosciences Ltd


List of Company Profiles

AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company (ARMO Biosciences.)
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd
(Genentech, Inc.,)
Sanofi
Merck & Co., Inc.
Merck KGaA (EMD Serono, Inc.)
BeiGene Ltd
Shanghai Jhunsi Biosciences Ltd.

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Top player positioning, 2020
3.4.Porter’s five forces analysis
3.4.1.Bargaining power of suppliers
3.4.2.Bargaining power of buyers
3.4.3.Threat of new entrants
3.4.4.Threat of substitutes
3.4.5.Intensity of competitive rivalry
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in incidences of cancer across the globe
3.5.1.2.Surge in global geriatric population
3.5.1.3.Supportive reimbursement policies for immune checkpoint inhibitors
3.5.2.Restraint
3.5.2.1.Higher cost of immune checkpoint inhibitors
3.5.3.Opportunities
3.5.3.1.Increase in number of pipeline drugs
3.5.3.2.Growth opportunities in emerging markets
3.5.4.Impact analyses
3.6.COVID-19 impact analysis on market
3.7.Clinical trials
3.8.Pipeline analyses
CHAPTER 4:IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.CTLA-4 inhibitor
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.3.PD-1 inhibitor
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.4.PD-L1 inhibitor
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
CHAPTER 5:IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Lung cancer
5.2.1.Market size and forecast
5.3.Bladder cancer
5.3.1.Market size and forecast
5.4.Melanoma
5.4.1.Market size and forecast
5.5.Hodgkin lymphoma
5.5.1.Market size and forecast
5.6.Others
5.6.1.Market size and forecast
CHAPTER 6:IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America market size and forecast, by country
6.2.2.1.U.S.
6.2.2.2.Canada
6.2.2.3.Mexico
6.2.3.North America market size and forecast, by type
6.2.4.North America market size and forecast, by application
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe market size and forecast, by country
6.3.2.1.Germany
6.3.2.2.France
6.3.2.3.UK
6.3.2.4.Rest of Europe
6.3.3.Europe market size and forecast, by type
6.3.4.Europe market size and forecast, by application
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Asia-Pacific market size and forecast, by country
6.4.2.1.Japan
6.4.2.2.China
6.4.2.3.Australia
6.4.2.4.India
6.4.2.5.Rest of Asia-Pacific
6.4.3.Asia-Pacific market size and forecast, by type
6.4.4.Asia-Pacific market size and forecast, by application
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.LAMEA market size and forecast, by country
6.5.2.1.Brazil
6.5.2.2.Rest of LAMEA
6.5.3.LAMEA market size and forecast, by type
6.5.4.LAMEA market size and forecast, by application
CHAPTER 7:COMPANY PROFILES
7.1.ASTRAZENECA PLC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product Portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.BRISTOL-MYERS SQUIBB COMPANY
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments
7.3.BEIGENE, LTD
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.ELI LILLY AND COMPANY
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.F. HOFFMANN-LA ROCHE AG
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.GLAXOSMITHKLINE PLC.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.MERCK & CO. INC. (PFIZER.)
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.MERCK KGAA (SIGMA ALDRICH)
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.SANOFI
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.SHANGHAI JUNSHI BIOSCIENCES CO LTD.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
LIST OF TABLES
TABLE 01.CLINICAL TRIALS IN IMMUNE CHECKPOINT INHIBITORS MARKET, 2015–2018
TABLE 02.PRODUCT PIPELINE ANALYSIS (PHASE II & III)
TABLE 03.GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2020–2030($MILLION)
TABLE 04.CTLA-4 INHIBITOR MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 05.PD-1 INHIBITOR MARKET, BY REGION, 2020–2030($MILLION)
TABLE 06.PD-L1 INHIBITOR MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 07.GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 08.LUNG CANCER IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2020–2030($MILLION)
TABLE 09.BLADDER CANCER IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2020–2030($MILLION)
TABLE 10.MELANOMA IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 11.HODGKIN LYMPHOMA IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 12.IMMUNE CHECKPOINT INHIBITORS MARKET FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 13.IMMUNE CHECKPOINT INHIBITORS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 14.NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 15.NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2020–2030($MILLION)
TABLE 16.NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 17.EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 18.EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2020–2030($MILLION)
TABLE 19.EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 20.ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 21.ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2020–2030($MILLION)
TABLE 22.ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 23.LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 24.LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2020–2030($MILLION)
TABLE 25.LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 26.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 27.ASTRAZENECA: OPERATING SEGMENTS
TABLE 28.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 29.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 30.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 31.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 32.BEIGENE: COMPANY SNAPSHOT
TABLE 33.FORTRESS: OPERATING SEGMENTS
TABLE 34.BEIGENE: PRODUCT PORTFOLIO
TABLE 35.LILLY: COMPANY SNAPSHOT
TABLE 36.LILLY: OPERATING SEGMENTS
TABLE 37.LILLY: PRODUCT PORTFOLIO
TABLE 38.ROCHE: COMPANY SNAPSHOT
TABLE 39.ROCHE: OPERATING SEGMENTS
TABLE 40.ROCHE: PRODUCT PORTFOLIO
TABLE 41.GSK: COMPANY SNAPSHOT
TABLE 42.GSK: PRODUCT SEGMENTS
TABLE 43.GSK: PRODUCT PORTFOLIO
TABLE 44.MERCK: COMPANY SNAPSHOT
TABLE 45.MERCK: OPERATING SEGMENTS
TABLE 46.MERCK: PRODUCT PORTFOLIO
TABLE 47.MERCK: COMPANY SNAPSHOT
TABLE 48.MERCK: OPERATING SEGMENTS
TABLE 49.MERCK: PRODUCT PORTFOLIO
TABLE 50.SANOFI: COMPANY SNAPSHOT
TABLE 51.SANOFI: OPERATING SEGMENTS
TABLE 52.SANOFI: PRODUCT TYPE PORTFOLIO
TABLE 53.SHANGHAI: COMPANY SNAPSHOT
TABLE 54.SHANGHAI: OPERATING SEGMENTS
TABLE 55.SHANGHAI: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.IMMUNE CHECKPOINT INHIBITORS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP PLAYER POSITIONING, 2020
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05.HIGH BARGAINING POWER OF BUYERS
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE THREAT OF SUBSTITUTES
FIGURE 08.MODERATR INTENSITY OF COMPETITIVE RIVALRY
FIGURE 09.IMPACT ANALYSES
FIGURE 10.U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 11.CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 12.MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 13.GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 14.FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 15.UK IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 16.REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 17.JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 18.CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 19.AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 20.INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 21.REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 22.BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 23.REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, 2020–2030($MILLION)
FIGURE 24.ASTRAZENECA: REVENUE, 2018–2020($MILLION)
FIGURE 25.ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2020(%)
FIGURE 26.ASTRAZENECA: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 27.REVENUE, 2018–2020 ($MILLION)
FIGURE 28.BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 29.BEIGENE: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.BEIGENE: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 31.LILLY: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.LILLY: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 33.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 34.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 35.ROCHE: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 36.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 37.GSK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 38.GSK: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 39.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 40.MERCK: REVENUE SHARE, BY SEGMENTS, 2020 (%)
FIGURE 41.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 42.MERCK: REVENUE, 2018–2020 ($MILLION)
FIGURE 43.MERCK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 44.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 45.SANOFI: REVENUE, 2018–2020 ($MILLION)
FIGURE 46.SANOFI: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 47.SANOFI: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 48.SHANGHAI: NET SALES, 2018–2020 ($MILLION)

$6,168
$4,125
$6,929
$10,663

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings